These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 30158420)

  • 1. [Azacitidine for Therapy-Related Myelodysplastic Syndrome Following Oxaliplatin (L-OHP)Therapy for Metastatic Rectal Cancer].
    Matsui T; Sakamoto N; Doi A; Fujii T; Ohno N; Sahara N; Irie S
    Gan To Kagaku Ryoho; 2018 Aug; 45(8):1201-1203. PubMed ID: 30158420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Azacitidine treatment for acute myeloid leukemia with myelodysplasia-related changes during peritoneal dialysis].
    Omatsu T; Udaka K; Shibata H; Sekimoto E; Ozaki S
    Rinsho Ketsueki; 2017; 58(12):2369-2374. PubMed ID: 29332868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A Case of Postoperative Recurrence of Rectal Cancer in Which Desensitization Therapy Was Effective against Oxaliplatin Allergy in L-OHP].
    Katagiri M; Miwa K; Shimomura S; Yomoda T; Tajiri K; Nagasu S; Fujino S; Koushi K; Fujita F; Kinugasa T; Akagi Y
    Gan To Kagaku Ryoho; 2018 May; 45(5):875-878. PubMed ID: 30026456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Azacitidine therapy for low-risk myelodysplastic syndrome developing after solid organ transplantation].
    Inoue H; Morita Y; Rai S; Kakutani H; Ohyama Y; Taniguchi Y; Tanaka H; Shimada T; Tatsumi Y; Ashida T; Matsumura I
    Rinsho Ketsueki; 2017; 58(2):138-142. PubMed ID: 28321091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Myelodysplastic syndrome with rapid disease progression after withdrawal of treatment with azacitidine].
    Ueda H; Yoshida M; Kanashima H; Nakao T; Sugiyama H; Yamane T
    Gan To Kagaku Ryoho; 2014 Jul; 41(7):875-7. PubMed ID: 25131875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
    Edlin R; Connock M; Tubeuf S; Round J; Fry-Smith A; Hyde C; Greenheld W
    Health Technol Assess; 2010 May; 14 Suppl 1():69-74. PubMed ID: 20507806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant capecitabine and oxaliplatin (XELOX) combined with bevacizumab for high-risk localized rectal cancer.
    Hasegawa J; Nishimura J; Mizushima T; Miyake Y; Kim HM; Takemoto H; Tamagawa H; Noura S; Fujii M; Fujie Y; Kato T; Miwa H; Takemasa I; Ikeda M; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M
    Cancer Chemother Pharmacol; 2014 May; 73(5):1079-87. PubMed ID: 24595805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of Complete Remission by Azacitidine in a Patient with Myelodysplastic Syndrome-Associated Inflammatory Bowel Disease.
    Kono M; Komeda Y; Sakurai T; Okamoto A; Minaga K; Kamata K; Hagiwara S; Inoue H; Enoki E; Matsumura I; Watanabe T; Kudo M
    J Crohns Colitis; 2018 Mar; 12(4):499-502. PubMed ID: 29253109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of advanced myelodysplastic syndrome with demethylating agents: azacitidine.
    Adès L; Itzykson R; Fenaux P
    Semin Hematol; 2012 Oct; 49(4):323-9. PubMed ID: 23079062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Successful treatment with azacitidine for a patient with relapsed myelodysplastic syndrome after cord blood transplantation].
    Ueda S; Miyakoshi S; Chizuka A; Kojima R; Ogasawara T; Miyamoto K
    Rinsho Ketsueki; 2013 Dec; 54(12):2177-81. PubMed ID: 24452149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of a 5-day regimen of azacitidine for patients with high-risk myelodysplastic syndromes.
    Fujimaki K; Miyashita K; Kawasaki R; Tomita N
    Eur J Haematol; 2016 Sep; 97(3):228-31. PubMed ID: 26613362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Unidentified Inflammatory Disease Induced by Azacitidine Therapy for Myelodysplastic Syndrome].
    Inagaki S; Tamai Y; Yoshizawa M; Sato S; Kanbe E; Tanaka E
    Gan To Kagaku Ryoho; 2015 Nov; 42(11):1443-6. PubMed ID: 26602409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Azacitidine in the treatment of pediatric therapy-related myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
    Inoue A; Kawakami C; Takitani K; Tamai H
    J Pediatr Hematol Oncol; 2014 Jul; 36(5):e322-4. PubMed ID: 24608072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.
    Silverman LR; Demakos EP; Peterson BL; Kornblith AB; Holland JC; Odchimar-Reissig R; Stone RM; Nelson D; Powell BL; DeCastro CM; Ellerton J; Larson RA; Schiffer CA; Holland JF
    J Clin Oncol; 2002 May; 20(10):2429-40. PubMed ID: 12011120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination Chemotherapy of Azacitidine and Cetuximab for Therapy-Related Acute Myeloid Leukemia following Oxaliplatin for Metastatic Colorectal Cancer.
    Hashimoto A; Takada K; Horiguchi H; Sato T; Iyama S; Murase K; Kamihara Y; Ono K; Tatekoshi A; Hayashi T; Miyanishi K; Sato Y; Furuhata T; Kobune M; Takimoto R; Hirata K; Kato J
    Case Rep Oncol; 2014 May; 7(2):316-22. PubMed ID: 24932174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies.
    Damaj G; Duhamel A; Robin M; Beguin Y; Michallet M; Mohty M; Vigouroux S; Bories P; Garnier A; El Cheikh J; Bulabois CE; Huynh A; Bay JO; Legrand F; Deconinck E; Fegueux N; Clement L; Dauriac C; Maillard N; Cornillon J; Ades L; Guillerm G; Schmidt-Tanguy A; Marjanovic Z; Park S; Rubio MT; Marolleau JP; Garnier F; Fenaux I; Yakoub-Agha I
    J Clin Oncol; 2012 Dec; 30(36):4533-40. PubMed ID: 23109707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison between hypersensitivity reactions to cycles of modified FOLFOX6 and XELOX therapies in patients with colorectal cancer.
    Ohta H; Hayashi T; Murai S; Shiouchi H; Ando Y; Kumazawa S; Ito K; Ikeda Y; Matsuoka H; Maeda K; Kawada K; Yasuda K; Yamada S
    Cancer Chemother Pharmacol; 2017 May; 79(5):1021-1029. PubMed ID: 28391355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study.
    Eisterer W; Piringer G; DE Vries A; Öfner D; Greil R; Tschmelitsch J; Samonigg H; Sölkner L; Gnant M; Thaler J;
    Anticancer Res; 2017 May; 37(5):2683-2691. PubMed ID: 28476845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment by azacitidine therapy of intestinal Behçet's disease associated with myelodysplastic syndrome.
    Tanaka H; Shimizu N; Tougasaki E; Kawajiri C; Hashimoto S; Takeda Y; Sakai S; Takeuchi M; Ohwada C; Sakaida E; Takagi T; Nakaseko C
    Int J Hematol; 2013 Apr; 97(4):520-4. PubMed ID: 23519573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5-azacitidine: An alternative treatment of myelodysplastic syndromes in patient with refractory response to hematopoietic growth factor, a case report and review of literatures.
    Suwanawiboon B; Sumida KN
    Hawaii Med J; 2004 Jan; 63(1):14-6, 25. PubMed ID: 15011897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.